GT Biopharma, Inc. Logo

GT Biopharma, Inc.

Clinical-stage immuno-oncology company developing therapies with its NK cell engager tech.

GTBP | US

Overview

Corporate Details

ISIN(s):
US36254L2097
LEI:
Country:
United States of America
Address:
505 MONTGOMERY STREET, 94111 SAN FRANCISCO

Description

GT Biopharma, Inc. is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE®) technology. The TriKE® platform generates therapeutic agents that are designed to simultaneously bind to Natural Killer (NK) cells and cancer cells. This targeted engagement activates and directs the cytotoxic function of NK cells to selectively destroy malignant cells. The company's pipeline targets a range of hematologic malignancies and solid tumors, including acute myeloid leukemia, myeloid dysplastic syndrome, and non-Hodgkin's lymphoma.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-03 01:15 English 5.3 KB
2025-12-02 23:24
424B3
English 91.0 KB
2025-11-26 22:30
8-K
English 74.5 KB
2025-11-14 22:00
10-Q
English 1.9 MB
2025-11-14 15:05
8-K
English 102.9 KB
2025-10-24 22:15
S-1
English 234.7 KB
2025-09-26 22:15
8-K
English 72.6 KB
2025-09-23 23:30
8-K
English 79.1 KB
2025-09-08 23:45 English 6.9 KB
2025-09-08 23:45 English 7.4 KB
2025-09-08 23:45 English 7.2 KB
2025-09-08 23:45 English 7.0 KB
2025-09-08 23:45 English 6.9 KB
2025-08-29 22:15
8-K
English 83.4 KB
2025-08-14 22:01
10-Q
English 2.6 MB

Automate Your Workflow. Get a real-time feed of all GT Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GT Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GT Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom affinity binders for research, diagnostics, and therapeutics.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
United States of America
APVO
Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
A product design and development firm providing services from concept to manufacturing.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
United States of America
ARVN
Asarina Pharma AB Logo
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
An integrated biologics development partner offering services from DNA sequence to cell bank.
South Korea
355690

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.